Rheumatoid Arthritis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Rheumatoid Arthritis Drugs Market Outlook

Rheumatoid Arthritis Drugs Market is expected to increase to US$ 49.86 Billion by 2030, according to Renub Research. Rheumatoid Arthritis (RA) is an autoimmune condition characterized by inflammation and joint pain. It occurs when the immune system malfunctions and targets the synovium, the lining of the joints. Generally, RA affects symmetrical joints on both sides of the body, like both hands and knees. The lungs, heart, eyes, and/or circulatory system are just a few examples of additional body systems that RA may occasionally affect. Approximately 40% of people with rheumatoid arthritis have symptoms in several bodily areas, including nerve tissue, eyes, lungs, salivary glands, and skin. The degree of signs and symptoms may vary, and in some situations, they may be completely absent. Females are more affected than males, with 2.5 females for every male. Rheumatoid Arthritis can appear as early as the age of 16 and last until the age of 40.

In a healthy individual, the immune system battles foreign invaders like bacteria and viruses. An autoimmune illness like RA occurs when the immune system mistakes the body's cells as foreign invaders and unleashes inflammatory chemicals that strike those cells. In RA, it targets the synovium, the tissue lining a joint that secretes a fluid to facilitate smooth movement of the joint. Moving the joint may be challenging due to the thickening of the inflammatory synovium, which makes the affected area of the joint feel uncomfortable, tender, and swollen.

In May 2023, Eli Lilly and Company's phase 2a research on peresolimab in rheumatoid arthritis (RA) revealed positive findings. Peresolimab indicated effectiveness and equal adverse event rates to the placebo group, therefore satisfying the primary aim of the research. These findings give preliminary clinical evidence of the utility of activating the endogenous PD-1 inhibitory pathway in the treatment of rheumatologic disorders. The study looked at the safety and efficacy of peresolimab in adults with moderate-to-severe RA who had not responded well to prior conventional, biologic, or synthetic disease-modifying antirheumatic medications (DMARDs).

Rheumatoid Arthritis Drugs market is projected to grow at a CAGR of 4.72% from 2022 to 2030

The global prevalence of rheumatoid arthritis (RA) was calculated to be 0.46 percent in the paper "The global prevalence of rheumatoid arthritis (RA): a meta-analysis based on a “stematic review" that was published in Rheumatology International. The market will grow as a result of increased adoption of therapies for the treatment of RA. The main forces behind the expansion of the global rheumatoid arthritis drugs market are the availability of pricey medications and efficient payment methods. The global rheumatoid arthritis drugs market is likely to benefit from the increasing prevalence of the condition, the emergence of biosimilars and biologics, and unambiguous tyrannical regulations.  It is anticipated that increasing medical service costs, particularly in developed areas, and developing knowledge about condition-specific therapies would contribute to income growth.

Increases in aged residents who are more susceptible to rheumatoid arthritis, increasing pervasiveness rates, and the deployment of new helpful experts are among the key expansion development drivers of the Global Rheumatoid Arthritis Drugs Market. The global rheumatoid arthritis drugs industry faces significant limitations and challenges due to factors like the lack of protection inclusion for some medications in developing countries, the patent expiration of some blockbuster drugs, and the inaccessibility of the treatment. As a result, Rheumatoid Arthritis Drugs Market was US$ 34.47 Billion in 2022.

Due to their faster and more efficient operation compared to oral treatments, injectable therapies for rheumatoid arthritis are currently dominating the market

By Product Type, Rheumatoid Arthritis Drugs Market is divided into Oral, Parenteral and Tropical. Injectable pharmaceuticals provide higher bioavailability, enhancing drugs absorption and improving therapeutic effects in rheumatoid arthritis. Given the disease's complexity, advanced biologics are necessary, typically requiring injection administration. Injectable-biologic medications are chosen by doctors to treat rheumatoid arthritis due to their ability to selectively target the underlying immunological systems of the disease and their established efficacy in providing customized care.

Biopharmaceuticals lead the rheumatoid arthritis treatment industry due to their precise targeting of immune pathways

Rheumatoid Arthritis Drugs Market is divided into pharmaceuticals and bio-pharmaceuticals based on therapeutic molecules. By lowering inflammation, preventing joint degeneration, and greatly enhancing pain relief, joint function, and quality of life, these cutting-edge drugs, like TNF inhibitors and interleukin inhibitors, revolutionize treatment. As rheumatoid arthritis processes are more understood, novel, and targeted biopharmaceutical therapies are being developed, solidifying their position as the top therapeutic modules on the market.

Pharmaceutical analgesics are rapidly growing in the rheumatoid arthritis treatment market due to their effectiveness in providing pain relief and compatibility with other medications

By Pharmaceuticals, Rheumatoid Arthritis Treatment Market is comprised of Disease-modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, Analgesics, Anti-tumour necrosis factor (TNF), and Others. Analgesics provide relief from the debilitating pain experienced by individuals with rheumatoid arthritis, addressing a primary concern. They provide a non-invasive therapy alternative, which appeals to people who choose to stay away from invasive treatments or have medical conditions that would preclude using other options. Patients choose pain treatments for rheumatoid arthritis from various formulations like pills, creams, and patches, often combining them with other medications. Their ability to be combined with other therapies enables a holistic strategy for rheumatoid arthritis pain and inflammation control, which has contributed to their quick market expansion.

Biosimilars have the highest share in the rheumatoid arthritis drugs market

By Bio-Pharmaceuticals, Rheumatoid Arthritis Drugs Market is sub-divied into Bio-pharmaceuticals, Biologics, and Biosimilars. Biosimilars offer comparable efficacy and safety to reference biologics at a lower cost, making them attractive to patients and healthcare providers. Patent expirations have created opportunities for biosimilar manufacturers, driving competition and market share. Regulatory authorities ensure their quality, safety, and efficacy, boosting confidence. Healthcare systems and insurance providers promote biosimilars to reduce costs and improve access to biologics.

The market for treating rheumatoid arthritis is seeing steroid surgery increase quickly due to several variables

By Surgery, Rheumatoid Arthritis Drugs Market is categorized into Nonsteroidal Anti-inflammatory Drugs Type, Steroids, and Biologic Agents. The powerful anti-inflammatory effects of steroids successfully reduce rheumatoid arthritis pain and inflammation. Direct joint injections that provide targeted relief improve symptom management. Due to the minimally invasive nature of steroid surgery, patients can quickly return to their regular activities after an outpatient procedure. Demand for steroid surgery as a non-surgical alternative is fuelled by an increasing desire for conservative methods. Systemic side effects related to oral corticosteroids are minimized by the targeted and transient nature of steroid injections. Steroid surgery is more affordable than biologic medications or surgery, which attracts consumers and healthcare systems and fuels its quick market expansion.

Prescription sales channels will dominate the rheumatoid arthritis drugs market due to the condition's complexity and the need for medical diagnosis and ongoing monitoring

By Sales Channel, Rheumatoid Arthritis Drugs Market is fragmented into Over-the-counter (OTC), and Prescription. Healthcare professionals play a crucial role in prescribing appropriate medications and providing personalized treatment plans. Prescription sales channels offer higher assurance in medication quality, authenticity, and safety, ensuring proper dosage instructions and patient monitoring. The development of innovative therapies, such as biologic drugs, requires specialized knowledge for prescription and administration, which prescription sales channels provide. The rise of telemedicine and digital healthcare platforms further supports the growth of prescription sales channels, offering convenient access to healthcare providers. Regulatory frameworks and healthcare policies also mandate authorized channels for dispensing prescription medications, ensuring compliance and patient safety.

Online distribution channels are set for substantial growth in the future of the rheumatoid arthritis drugs market.

By Distribution Channel, Rheumatoid Arthritis drugs Market is broken up into Hospital Pharmacies, Retail Pharmacies, and Online. Patients can now order drugs from home thanks to the growth of e-commerce and digital platforms, which have increased the accessibility and convenience of healthcare items. As telemedicine is used more frequently, virtual consultations and electronic prescriptions are made possible, making it easier to buy medications online. Patients gain by having access to a variety of products, lower prices, and information and support services. These elements have a role in the market for treating rheumatoid arthritis' considerable expansion of online distribution channels.

In North America, rheumatoid arthritis drugs should continue to hold a substantial market share

Based on Region, Rheumatoid Arthritis drugs Market is divided into North America, South America, Europe, Asia-Pacific, and Rest of World. The rising disease prevalence, the dominance of major market players, the rising introduction of novel therapies like monoclonal antibodies for rheumatoid arthritis, and the rising investments made by major market players in the development of new therapies and biosimilars for this condition are all expected to contribute to the market for the region under study expanding.

The Centers for Disease Control and Prevention (CDC) estimate that approximately 1 in 4 adults in the United States (23.7%), or 58.5 million people, have arthritis as determined by medical professionals. The high prevalence of rheumatoid arthritis and the corresponding demand for pharmaceutical treatments are driving market expansion.

United States will register substantial growth in the rheumatoid arthritis treatment market

The Rheumatoid Arthritis drugs Market is segmented into the following countries: the United States, Canada, Mexico, the United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Indonesia, Brazil, Argentina, Saudi Arabia, the United Arab Emirates, South Africa, and Other Countries. Due to its powerful regulatory environment, big patient population, innovative pharmaceutical industry, and strong healthcare infrastructure, the US leads the world in rheumatoid arthritis treatment. It is possible to receive a prompt diagnosis, have access to specialists, and choose from a variety of treatments. The United States is a centre for pharmaceutical research that produces cutting-edge treatments. Investment in research and development is attracted by the strong market demand and the supportive environment. The US FDA provides assurances of efficacy and safety, fostering trust. The availability and affordability of treatments are improved by insurance coverage.

Competitive Landscape

Among the top competitors present in the rheumatoid arthritis drugs market are Eli Lilly and Co., Fibrogen Inc., Biogen Inc., Merck & Co. Inc., Abbvie Inc., Roche Holding AG, Novartis AG, and Johnson & Johnson.

In February 2022- Biogen Inc. and XbraneBiopharma AB signed a commercialization and license agreement to create, produce, and sell Xcimzane. The rheumatoid arthritis medication CIMZIA (certolizumabpegol) has a suspected biosimilar in this preclinical monoclonal antibody.

Renub Research latest report “Rheumatoid Arthritis Drugs Market, Product Types (Oral, Parenteral, Tropical), Therapeutic Molecules (Pharmaceuticals, and Bio-pharmaceuticals), Pharmaceuticals (Disease-modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, Analgesics, Anti-tumour necrosis factor (TNF), and Others), Bio-Pharmaceuticals (Bio-pharmaceuticals, Biologics, and Biosimilars), Surgery (Nonsteroidal Anti-inflammatory Drugs Type, Steroids, and Biologic Agents), Sales Channel (Over-the-counter (OTC), and Prescription), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online), Regions (North America, South America, Europe, Asia-Pacific, and ROW), Countries (United States, Canada, Mexico, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Indonesia, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Other Countries), Companies (Eli Lilly and Co., Fibrogen Inc., Biogen Inc., Merck & Co. Inc, Abbvie Inc., Roche Holding AG, Novartis AG, Johnson & Johnson)” provides a detailed analysis of Rheumatoid Arthritis Drugs Industry.

Product Types – Market has been covered from 3 viewpoints:

1.    Oral
2.    Parenteral
3.    Tropical

Therapeutic Molecules – Market has been covered from 2 viewpoints:

1.    Pharmaceuticals
2.    Bio-pharmaceuticals

Pharmaceuticals – Market has been covered from 7 viewpoints:

1.    Disease-modifying Anti-rheumatic Drugs (DMARDs)
2.    Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
3.    Corticosteroids
4.    Uric Acid Drugs
5.    Analgesics
6.    Anti-tumour necrosis factor (TNF)
7.    Others

Bio-Pharmaceuticals – Market has been covered from 3 viewpoints:

1.    Bio-pharmaceuticals
2.    Biologics
3.    Biosimilars

Surgery – Market has been covered from 3 viewpoints:

1.    Nonsteroidal Anti-inflammatory Drugs Type
2.    Steroids
3.    Biologic Agents

Sales Channel – Market has been covered from 2 viewpoints:

1.    Over-the-counter (OTC)
2.    Prescription

Distribution Channel – Market has been covered from 3 viewpoints:

1.    Hospital Pharmacies
2.    Retail Pharmacies
3.    Online

Region – Market has been covered from 5 viewpoints:

1.    North America
2.    South America
3.    Europe
4.    Asia-Pacific
5.    Rest of World

Countries – Market has been covered from 22 Countries:

1.    North America

1.1    United States
1.2    Canada
1.3    Mexico

2.    Europe

2.1    United Kingdom
2.2    Germany
2.3    France
2.4    Russia
2.5    Italy
2.6    Spain
2.7    Switzerland

3.    Asia-Pacific

3.1    India
3.2    China
3.3    Japan
3.4    Australia
3.5    South Korea
3.6    Indonesia

4.    Middle East & Africa

4.1    Saudi Arabia
4.2    United Arab Emirates
4.3    South Africa

5.    South America

5.1    Argentina
5.2    Brazil
5.3    Other Countries

6.    Rest of World

Company Insights:

•    Overview
•    Recent Development
•    Revenue

Company Analysis:

1.    Eli Lilly and Co.
2.    Fibrogen Inc.
3.    Biogen Inc.
4.    Merck & Co. Inc
5.    Abbvie Inc.
6.    Roche Holding AG
7.    Novartis AG
8.    Johnson & Johnson

Report Details: